Johnson & Johnson JNJ said Tuesday it has agreed to acquire V-Wave Ltd., a privately held company developing treatments for patients with heart failure, for $600 million upfront and potential extra payments of up to $1.1 billion. V-Wave will become part of Johnson & Johnson Medtech. The deal will help J&J “accelerate its shift into high-growth and high-opportunity markets and will deepen its re...
Johnson & Johnson said on Tuesday it would buy medical device maker V-Wave in a deal potentially worth up to $1.1 billion, marking the latest acquisition to bolster its devices unit.
The stock market is dynamic, often characterized by periods of volatility and uncertainty. These periods can be particularly challenging for investors susceptible to the pervasive influence of Fear, Uncertainty, and Doubt (FUD).
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson1 (NYSE: JNJ) today announced that it has entered into a definitive agreement to acquire V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. Under the terms of the agreement, Johnson & Johnson will acquire V-Wave for an upfront payment of $600 million, subject to customar...
The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination therapy for patients with a type of non-small cell lung cancer.
Johnson & Johnson JNJ, +0.15% said Tuesday the U.S. Food and Drug Administration has approved a combination treatment for a type of lung cancer that's the first chemotherapy-free regimen. The FDA has approved the combination of Rybrevant plus Lazcluze for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer, or NSCLC, with epidermal growth factor...
RYBREVANT® plus LAZCLUZE™ is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib Following Priority Review, approval is based on Phase 3 MARIPOSA results showing RYBREVANT® plus LAZCLUZE™ reduced the risk of disease progression or death by 30 percent versus osimertinib, with a nine-month-longer median duration of response RARITAN, N.J. , Au...
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.